Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DENOSUMAB Cause Multiple fractures? 415 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 415 reports of Multiple fractures have been filed in association with DENOSUMAB (Bilprevda). This represents 0.3% of all adverse event reports for DENOSUMAB.

415
Reports of Multiple fractures with DENOSUMAB
0.3%
of all DENOSUMAB reports
7
Deaths
66
Hospitalizations

How Dangerous Is Multiple fractures From DENOSUMAB?

Of the 415 reports, 7 (1.7%) resulted in death, 66 (15.9%) required hospitalization, and 3 (0.7%) were considered life-threatening.

Is Multiple fractures Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DENOSUMAB. However, 415 reports have been filed with the FAERS database.

What Other Side Effects Does DENOSUMAB Cause?

Off label use (34,612) Death (16,545) Osteonecrosis of jaw (8,438) Arthralgia (5,890) Pain in extremity (4,541) Back pain (4,465) Pain (4,102) Product storage error (3,621) Fall (3,322) Fatigue (3,009)

What Other Drugs Cause Multiple fractures?

EMTRICITABINE\TENOFOVIR DISOPROXIL (8,088) TENOFOVIR DISOPROXIL (6,793) EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL (4,102) COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL (1,942) EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL (1,489) NEXIUM (346) ADALIMUMAB (305) ETANERCEPT (251) ABATACEPT (217) TOCILIZUMAB (200)

Which DENOSUMAB Alternatives Have Lower Multiple fractures Risk?

DENOSUMAB vs DEOXYCHOLIC ACID DENOSUMAB vs DEPAKINE CHRONO DENOSUMAB vs DEPAKOTE DENOSUMAB vs DEPO-PROVERA DENOSUMAB vs DERMATOPHAGOIDES FARINAE

Related Pages

DENOSUMAB Full Profile All Multiple fractures Reports All Drugs Causing Multiple fractures DENOSUMAB Demographics